

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): June 15, 2011

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-32085
(Commission
File Number)

36-4392754
(IRS Employer
Identification No.)

222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (312) 506-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 hereto is an Investor Presentation dated June 15, 2011, which is incorporated herein by reference.

The information contained in, or incorporated into, this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits.**(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation dated June 15, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: June 15, 2011

By: /s/ William J. Davis
William J. Davis
Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation dated June 15, 2011

A Connected
Community
of Health™

ORGANIZATIONS + 180,000 MDS + 50,000 PHYSICIAN PRACTICES + 1,500 HOSPITALS + 10,000 POST ACUTE CARE

**William Blair & Company Growth Stock Conference
Investor Presentation
June 15, 2011**



Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the risk that we will not achieve the strategic benefits of the merger (the "Eclipsys Merger") with Eclipsys Corporation ("Eclipsys"); the possibility that the expected synergies and cost savings of the Eclipsys Merger will not be realized, or will not be realized within the expected time period; the risk that our business will not be integrated successfully with the business of Eclipsys; disruption from the Eclipsys Merger and related transactions making it more difficult to maintain business relationships with customers, partners and others; unexpected requirements to achieve interoperability certification pursuant to the Health Information Technology for Economic and Clinical Health Act, with resulting increases in development and other costs for us; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; errors or similar problems in our software products; the outcome of any legal proceeding that has been or may be instituted against us and others; compliance obligations under existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009, as well as elements of the Patient Protection and Affordable Care Act (aka health reform) which pertains to health IT adoption; maintaining our intellectual property rights and litigation involving intellectual property rights; legislative, regulatory and economic developments; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology and breach of our security by third parties. See our Transition Report on Form 10-K for the seven months ended December 31, 2010 and our subsequent filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.

A Connected
Community
of Health™

Our Vision



To be the most trusted provider of innovative solutions that empower all stakeholders across the healthcare continuum to deliver world-class outcomes.

Our Mission



Allscripts Corporate Snapshot



Our Clients

- 180,000 Providers
- 50,000 Physician Practices
- 1,500 Hospitals
- 10,000 Post Acute Facilities
- 27,000 Clinicians In Patients' Homes Every Day



Our Company

- One Complete Set of Solutions
- 5,800 Employees
- \$1.3BB 2010 Non-GAAP Revenue
- \$148MM 2010 Non-GAAP Net Income

Allscripts Key Competitive Differentiation: Leading Market Share Across Acute, Ambulatory and Post-Acute Providers, a Key Consideration for Accountable Care Organizations (ACOs)

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation. Information also available at <http://investor.allscripts.com>

Investment Highlights

- Leading healthcare IT company with the broadest set of capabilities across every venue of care including physicians, hospitals, post-acute and homecare
- The most utilized clinical solutions enabling health care providers to fully capitalize on the \$30BB federal stimulus program
- Leadership in technology and innovation uniquely positions Allscripts to aggressively compete for the \$43BB healthcare IT solutions market
- A highly attractive financial profile with high recurring revenue, significant operating leverage and cost synergy opportunities and strong free cash flow

The Time is NOW

A National Problem

- Quality Issues
- Medical Errors / Safety Concerns
- Rising Cost
- Significant Waste



A Market that is Ready

- \$43BB⁽¹⁾ Opportunity
- \$30BB in Stimulus Funding
- ~15% Penetration in Physician Practices
- Rise of the Employed Physicians
- Hospitals Driving Adoption



A Significant Opportunity

We are at the *beginning* of what we expect will be the single fastest transformation of any industry in US history

(1) McKinsey & Company

Addressing the Entire Market Opportunity

Acute/Ambulatory EHR Opportunity 2010-2014 = ~\$43BB



Source: McKinsey & Company


A Complete Portfolio Addresses the Entire Care Continuum

Ambulatory Market Potential

Practice Size	Total # of Practices	EHR Penetration (FY09/10)
1-3 Physicians	163,000	~13%
4-9 Physicians	27,000	~22%
10-25 Physicians	8,000	~33%
26+ Physicians	2,000	~50%
Total	200,000	~15%

Source: SK&A = SK&A Information Services which sells databases for sales and marketing success in healthcare industry

Increased Certainty for Widespread EHR Adoption



Source: National Center for Health Statistics

(1) ~20% estimate based on number of ambulatory physicians; penetration as a percentage of number of physician practices is ~11%

(2) Hospitals >200 beds

Allscripts: Competitive Differentiation

One Network.

The largest connected network in the nation... and in your community.

- The Largest Network with a Client Base of 180,000 Physicians, 1,500 Hospitals and 10,000 Post-Acute Care Providers
- The Unique Ability to Truly Connect a Community

One Platform.

Open, flexible, and innovative to help you connect inside and outside your organization.


- Comprehensive, Integrated Solutions for all Settings
- Rapid Implementation Approach to Attain "Meaningful Use"
- A Track Record of Innovation with a 'Future State' Clinical/Financial Informatics Capability
- Common Microsoft platform and a shared 'open architecture' approach, simplifying the connection to third-party applications across every care setting

One Patient.

A complete portfolio that delivers a single patient record across your community.

- One Patient Record Across an Organization and the Community – One Source of Truth

One Network: The Largest Community in the Nation




- **The 'Hub':** Over 1,500 Hospitals including 40% of "America's Best Hospitals" as Clients
- **The 'Spokes':** Over 180,000 MDs and 10,000 Post-Acute Care Organizations are Connected to other Practices, Patients, Pharmacies, Payors, Clinical Labs and Hospitals


One Platform: A Complete, Integrated Solutions Portfolio

	Clinical	Financial	Administrative	Analytics	Services
Acute Solutions (Sunrise)	Clinical Manager	Patient Financials	Enterprise Registration	EPSi	Outsourcing
	Emergency Care	Financial Manager	Enterprise Scheduling	Decision Support	Remote Hosting
	Pharmacy		Access Management	Patient Flow	Consulting
	Laboratory		Record Manager	Clinical Analytics	Network/Desktop
	Knowledge-Based Charting		Enterprise Identifier		Education
	Acute Content				
	Knowledge-Based Medication Administration				
	Radiology				
Ambulatory Solutions	Electronic Health Record		CQS	Transformation	
	Payerpath		Analytics	Academy	
	ePrescribe				
	Practice Management				
Post-Acute Solutions	Homecare / Hospice				
	Utilization Management				
	Discharge Planning				
	Referral Management				
Community Solutions	Community Exchange				
	Community Record				
	Helios				

One Patient: Critical Patient Data Flows Freely



The New Architecture of Healthcare



Financial Overview

1Q 2011 Highlights

Bookings Growth Reflects Breadth of Market Solutions

- Total bookings of \$500MM in the two full quarters, post-merger, a 22% year-over-year increase
- Three new Sunrise Enterprise client sales YTD (two in Q1 2011)
- Strong ambulatory purchasing across all practice sizes
- Software-as-a-Service (SaaS) bookings 21% of total

Strong Revenue, Margin Growth

- Non-GAAP revenue grew 10.5% year-over-year to \$346.1MM
- 66% recurring revenue in the quarter
- Professional services grew 34% year-over-year
- Non-GAAP operating margins expanded to 20.8% from 19.1%


Healthy Platform for Future Growth

- \$2.7BB revenue backlog
- Generated \$67MM in operating cash flow - strong Q1 showing
- Repaid \$122MM in debt in 8 months, post merger
- Refinanced debt agreement at more favorable terms
- Announced a \$200MM share repurchase program


Revenue, operating margin on a non-GAAP basis

Historical Consolidated Performance

Non-GAAP Revenue
CY 2009: \$1,188MM



Non-GAAP Revenue
CY 2010: \$1,300MM



Combined Non-GAAP Operating Income (\$millions)



Note: Ambulatory revenue refers to legacy Allscripts, as reported; Acute revenue refers to legacy Eclipsys, as reported


Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation. Information also available at <http://investor.allscripts.com>

Significant Key Cost Synergies

Key Cost Synergy Drivers

- Duplicative management structure
- Duplicative public company costs
- Duplicative back-end office and system integration
- Marketing

Projected Cost Synergies Over Three Years



Non-GAAP Financial Outlook⁽¹⁾

(\$ in millions; except per share amounts)

	<u>CY 2010 Actual</u>	<u>CY 2011</u>	<u>2010 to 2011 Change</u>
Non-GAAP Revenue	\$1,300	\$1,425 - \$1,450	10 - 12%
Non-GAAP Operating Margin	19%	21%	--
Non-GAAP Net Income	\$148	\$167 - \$176	13 - 19%
Non-GAAP Diluted EPS	\$0.76	\$0.86 - \$0.90	13 - 18%

(1) Guidance provided by the company in a press release on May 5, 2011. This presentation does not subsequently update or reaffirm Allscripts financial guidance.

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation. Information also available at <http://investor.allscripts.com>

Strong Free Cash Flow Generation

	Actual 3/31/2011
Capitalization	
Cash and Marketable Securities	\$147
Revolver (\$250mm)	0
Term Loan	448
Total Debt	\$448
Equity	1,428
Total Capitalization	\$1,876
Credit Statistics	
LTM EBITDA ⁽¹⁾	\$314
Total Debt / LTM EBITDA ⁽¹⁾	1.4x
Debt / Capitalization	23.9%

- Reduced debt by \$122MM since merger closed
- Required principal payments in 2011 total \$27.8MM
- Current borrowing cost <3%
- Completed amendment to borrowing agreements, reducing cash borrowing costs by 75 BPS

1 EBITDA is calculated as net income plus income tax expense, interest expense, stock-based compensation expense, depreciation & amortization, deferred revenue adjustments, certain one-time and transaction-related expenses, and non-recurring losses on the sale of investments minus non-recurring gains on the sale of assets, consistent with the calculation as defined in the Company's Senior Credit Facilities agreement.

Note: Please see the Non-GAAP reconciliation and related footnotes in the appendix to this presentation. Information also available at <http://investor.allscripts.com>

One Network.
One Platform.
One Patient.



Appendix: Non-GAAP Reconciliation

GAAP – non-GAAP revenue and net income reconciliation for the twelve months ended December 31, 2010.

Allscripts Healthcare Solutions, Inc.
2010 Non-GAAP Financial Information
(In millions)
(unaudited)

	2010 Results Non-GAAP
Total revenue, as reported	\$1,191.5
Deferred revenue adjustment	29.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	79.5
Total non-GAAP revenue	<u>\$1,300.3</u>
Net income, as reported	\$36.4
Deferred revenue adjustment	17.7
Acquisition-related amortization	27.7
Stock-based compensation expense	16.9
Transaction-related expense	38.2
ARS Sales	0.9
Tax rate alignment	6.8
Eclipsys results pre-merger period (7/1/10-8/23/10)	2.9
Non-GAAP net income	<u>\$147.5</u>

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue growth for the three months ended March 31, 2011.

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

	<u>Three Months Ended</u> <u>3/31/11</u>	<u>Three Months Ended</u>		
		<u>3/31/10</u> <u>Allscripts</u>	<u>3/31/10</u> <u>Eclipsys</u>	<u>Q1 2010</u> <u>Total</u>
Total revenue, as reported	\$335.3	\$184.4	\$128.4	\$312.8
Deferred revenue adjustment	10.8	0.5	0.0	0.5
Total non-GAAP revenue	<u>\$346.1</u>	<u>\$184.9</u>	<u>\$128.4</u>	<u>\$313.3</u>

Appendix: Non-GAAP Reconciliation

GAAP – non-GAAP operating income and margin reconciliation for the three months ended March 31, 2011 and 2010.

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

	<u>Three Months Ended</u> <u>3/31/11</u>	<u>Three Months Ended</u>		
		<u>3/31/10</u> <u>Allscripts</u>	<u>3/31/10</u> <u>Eclipsys</u>	<u>Q1 2010</u> <u>Total</u>
Total revenue, as reported	\$335.3	\$184.4	\$128.4	\$312.8
Deferred revenue adjustment	10.8	0.5	0.0	0.5
Total non-GAAP revenue	<u>\$346.1</u>	<u>\$184.9</u>	<u>\$128.4</u>	<u>\$313.3</u>
Operating income, as reported	\$24.5	\$32.0	\$10.7	\$42.7
Deferred revenue adjustment	10.8	0.5	0.0	0.5
Acquisition-related amortization	16.7	5.6	3.1	8.7
Stock-based compensation expense	7.0	3.9	3.7	7.6
Transaction-related expense (a)	13.1	0.2	0.0	0.2
Total non-GAAP operating income	<u>\$72.1</u>	<u>\$42.2</u>	<u>\$17.5</u>	<u>\$59.7</u>
Total non-GAAP operating income as a percentage of non-GAAP revenue	20.8%			19.1%

Appendix: Non-GAAP Reconciliation

GAAP – non-GAAP revenue reconciliation for the twelve months ended November 30, 2009 (Allscripts) and twelve months ended December 31, 2009 (Eclipsys).

Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

	<u>Twelve Months Ended</u>		
	<u>Allscripts</u> <u>(11/30/2009)</u>	<u>Eclipsys</u> <u>(12/31/2009)</u>	<u>Non-GAAP</u>
Total revenue, as reported	\$661.1	\$519.1	\$1,180.2
Deferred revenue adjustment	9.7	8.0	\$17.7
Elimination of prepackaged medications	(9.7)	0.0	(\$9.7)
Total non-GAAP revenue	<u>\$661.1</u>	<u>\$527.1</u>	<u>\$1,188.2</u>

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP operating income reconciliation by quarter and twelve months ended December 31, 2009 (Eclipsys) and November 30, 2009 (Allscripts).

Allscripts Healthcare Solutions, Inc.
2009 Non-GAAP Financial Information
(In millions, except per-share amounts)
(Unaudited)

2009 Actual Results By Quarter

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended			Twelve Months Ended		
	2/28/09	3/31/09	Q1 2009	5/31/09	6/30/09	Q2 2009	8/31/09	9/30/09	Q3 2009	11/30/09	12/31/09	Q4 2009	11/30/09	12/31/09	CY 2009
	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP
Operating income, as reported	\$22.8	(\$0.1)	\$22.7	\$23.6	(\$2.2)	\$21.4	\$21.6	\$4.5	\$26.1	\$26.7	\$7.2	\$33.9	\$94.7	\$9.4	\$104.1
Deferred revenue adjustment	3.1	1.5	4.6	2.6	3.1	5.7	2.6	0.5	3.1	1.4	1.8	3.2	9.7	6.9	16.6
Acquisition-related amortization	6.1	3.1	9.2	5.7	3.1	8.8	5.7	3.1	8.8	5.7	3.1	8.8	23.2	12.4	35.6
Stock-based compensation expense	2.1	4.4	6.5	2.6	6.8	9.4	3.3	3.6	6.9	4.4	3.4	7.8	12.4	18.2	30.6
Transaction-related expense	3.5	0.0	3.5	7.2	0.0	7.2	3.9	0.0	3.9	1.3	0.0	1.3	15.9	0.0	15.9
Restructuring	0.0	5.4	5.4	0.0	3.2	3.2	0.0	1.1	1.1	0.0	0.0	0.0	0.0	9.7	9.7
Elimination of prepackaged medications	(1.0)	0.0	(1.0)	(0.1)	0.0	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	(1.1)	0.0	(1.1)
Total non-GAAP operating income	\$36.6	\$14.3	\$50.9	\$41.6	\$14.0	\$55.6	\$37.1	\$12.8	\$49.9	\$39.5	\$15.5	\$55.0	\$154.8	\$56.6	\$211.5

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP operating income reconciliation by quarter and twelve months ended December 31, 2010.

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information 2010 Proforma Financial Information
(In millions)
(unaudited)

2010 Actual Results By Quarter

	Three Months Ended			Three Months Ended			Three Months Ended			Three Months Ended 12/31/10	2010 Full Year Results
	2/28/10	3/31/10	Q1 2010	5/31/10	6/30/10	Q2 2010	9/30/10	9/30/10	Q3 2010		
	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Q4 2010	Non-GAAP
Operating income, as reported	\$31.9	\$10.7	\$42.6	\$24.5	\$5.4	\$29.9	\$5.5	(\$7.2)	(\$1.7)	\$9.5	\$80.3
Deferred revenue adjustment	0.5	0.0	0.5	0.6	0.0	0.6	0.5	6.7	7.2	20.9	29.2
Acquisition-related amortization	5.6	3.1	8.7	5.7	3.1	8.8	5.6	4.9	10.5	17.4	45.4
Stock-based compensation expense	4.3	3.7	8.0	2.8	3.7	6.5	6.6	0.0	6.6	3.7	24.8
Transaction-related expense	0.0	0.0	0.0	9.1	3.5	12.6	26.6	9.1	35.7	17.8	66.1
Restructuring	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	-	0.0
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	4.7	-	4.7
Total non-GAAP operating income	\$42.3	\$17.5	\$59.8	\$42.7	\$15.7	\$58.4	\$44.8	\$18.2	\$63.0	\$69.3	\$250.5

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP EBITDA reconciliation for the 12 months ended March 31, 2011

EBITDA Calculation

(\$ in thousands)

	Pro Forma Combined 12 months ended 3/31/2011
Net income	\$14.6
Income tax expense	15.1
Stock-based compensation expense	36.5
Depreciation & amortization	108.1
Interest expense	18.1
Transaction related/integration-related expenses	75.7
Deferred revenue adjustment	39.4
Loss on sale of investments/ARS	6.4
EBITDA	<u>\$314.0</u>

Footnotes Regarding Financial Guidance

Financial guidance was last provided by the company in a press release on May 5, 2011. This presentation does not subsequently update or reaffirm Allscripts financial guidance.

Allscripts non-GAAP guidance for calendar 2011 assumes the following adjustments to approximately \$1,418.0 million in GAAP revenue: approximately \$21.0 million, pre-tax in deferred revenue adjustments. Non-GAAP guidance for calendar 2011 assumes the following adjustments to GAAP operating and net income: approximately \$70.0 million of acquisition-related amortization; approximately \$40.0 million in stock-based compensation expense; approximately \$21.0 million in deferred revenue adjustments; all on a pre-tax basis. Allscripts 2011 non-GAAP net income and diluted earnings per share guidance assumes a 38.0%-39.5% tax rate.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, in this presentation Allscripts provides total non-GAAP revenue, gross profit, operating income and net income, including non-GAAP net income on a per share basis, which are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Total non-GAAP revenue consists of GAAP revenue as reported and Eclipsys revenue for periods prior to the August 24, 2010 consummation of the 2010 merger with Eclipsys (2010 Merger) and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Total non-GAAP gross profit consists of GAAP gross profit as reported and Eclipsys gross profit for periods prior to the consummation of the 2010 Merger and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes. Total non-GAAP operating income consists of GAAP operating income as reported and Eclipsys operating income for periods prior to the consummation of the 2010 Merger and adds back the acquisition-related deferred revenue adjustment booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense and transaction-related expenses. Non-GAAP net income consists of GAAP net income as reported and includes Eclipsys net income for periods prior to the consummation of the 2010 Merger, excludes acquisition-related amortization, stock-based compensation expense and transaction-related expenses, adds back the acquisition-related deferred revenue adjustment, in each case net of any related tax effects.

Management believes that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis provide useful supplemental information to management and investors regarding the underlying performance of the company's business operations and facilitates comparisons of the separate 2010 pre-merger results of legacy Allscripts and legacy Eclipsys to that of the company's 2010 post-merger results. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that we have provided and discussed herein. Management also uses this information internally for forecasting and budgeting as it believes that the measure is indicative of the company's core operating results. In addition, the company uses non-GAAP revenue, operating income and/or net income to measure achievement under the company's stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis are performance measures only, and they do not provide any measure of the company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP.